SLC43A3 and acute lymphoblastic leukemia: It is possible that variations in the expression of ENBT1, and/or polymorphisms in the SLC43A3 gene, may underlie some of the observed inter-individual differences in 6-MP pharmacokinetics and the incidence and severity of its adverse effects when used in the treatment of acute lymphoblastic leukemia and intestinal bowel diseases.